We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still Room to Run?
Read MoreHide Full Article
Have you been paying attention to shares of Adma Biologics (ADMA - Free Report) ? Shares have been on the move with the stock up 22.9% over the past month. The stock hit a new 52-week high of $17.04 in the previous session. Adma Biologics has gained 263.9% since the start of the year compared to the 6.7% move for the Zacks Medical sector and the -2.3% return for the Zacks Medical - Biomedical and Genetics industry.
What's Driving the Outperformance?
The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on August 8, 2024, Adma Biologics reported EPS of $0.13 versus consensus estimate of $0.08 while it beat the consensus revenue estimate by 23.17%.
For the current fiscal year, Adma Biologics is expected to post earnings of $0.41 per share on $410.3 million in revenues. Meanwhile, for the next fiscal year, the company is expected to earn $0.59 per share on $466.3 million in revenues. This represents a year-over-year change of 44.71% and 13.65%, respectively.
Valuation Metrics
Adma Biologics may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level.
On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. Investors should consider the style scores a valuable tool that can help you to pick the most appropriate Zacks Rank stocks based on their individual investment style.
Adma Biologics has a Value Score of D. The stock's Growth and Momentum Scores are A and A, respectively, giving the company a VGM Score of B.
In terms of its value breakdown, the stock currently trades at 40.5X current fiscal year EPS estimates, which is a premium to the peer industry average of 25X. On a trailing cash flow basis, the stock currently trades at 323.7X versus its peer group's average of 16.8X. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.
Zacks Rank
We also need to consider the stock's Zacks Rank, as this supersedes any trend on the style score front. Fortunately, Adma Biologics currently has a Zacks Rank of #2 (Buy) thanks to rising earnings estimates.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Adma Biologics meets the list of requirements. Thus, it seems as though Adma Biologics shares could have potential in the weeks and months to come.
How Does ADMA Stack Up to the Competition?
Shares of ADMA have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is Exelixis, Inc. (EXEL - Free Report) . EXEL has a Zacks Rank of # 2 (Buy) and a Value Score of B, a Growth Score of B, and a Momentum Score of A.
Earnings were strong last quarter. Exelixis, Inc. beat our consensus estimate by 127.03%, and for the current fiscal year, EXEL is expected to post earnings of $1.79 per share on revenue of $2.04 billion.
Shares of Exelixis, Inc. have gained 19.4% over the past month, and currently trade at a forward P/E of 15.05X and a P/CF of 34.97X.
The Medical - Biomedical and Genetics industry is in the top 29% of all the industries we have in our universe, so it looks like there are some nice tailwinds for ADMA and EXEL, even beyond their own solid fundamental situation.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
ADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still Room to Run?
Have you been paying attention to shares of Adma Biologics (ADMA - Free Report) ? Shares have been on the move with the stock up 22.9% over the past month. The stock hit a new 52-week high of $17.04 in the previous session. Adma Biologics has gained 263.9% since the start of the year compared to the 6.7% move for the Zacks Medical sector and the -2.3% return for the Zacks Medical - Biomedical and Genetics industry.
What's Driving the Outperformance?
The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on August 8, 2024, Adma Biologics reported EPS of $0.13 versus consensus estimate of $0.08 while it beat the consensus revenue estimate by 23.17%.
For the current fiscal year, Adma Biologics is expected to post earnings of $0.41 per share on $410.3 million in revenues. Meanwhile, for the next fiscal year, the company is expected to earn $0.59 per share on $466.3 million in revenues. This represents a year-over-year change of 44.71% and 13.65%, respectively.
Valuation Metrics
Adma Biologics may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level.
On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. Investors should consider the style scores a valuable tool that can help you to pick the most appropriate Zacks Rank stocks based on their individual investment style.
Adma Biologics has a Value Score of D. The stock's Growth and Momentum Scores are A and A, respectively, giving the company a VGM Score of B.
In terms of its value breakdown, the stock currently trades at 40.5X current fiscal year EPS estimates, which is a premium to the peer industry average of 25X. On a trailing cash flow basis, the stock currently trades at 323.7X versus its peer group's average of 16.8X. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.
Zacks Rank
We also need to consider the stock's Zacks Rank, as this supersedes any trend on the style score front. Fortunately, Adma Biologics currently has a Zacks Rank of #2 (Buy) thanks to rising earnings estimates.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Adma Biologics meets the list of requirements. Thus, it seems as though Adma Biologics shares could have potential in the weeks and months to come.
How Does ADMA Stack Up to the Competition?
Shares of ADMA have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is Exelixis, Inc. (EXEL - Free Report) . EXEL has a Zacks Rank of # 2 (Buy) and a Value Score of B, a Growth Score of B, and a Momentum Score of A.
Earnings were strong last quarter. Exelixis, Inc. beat our consensus estimate by 127.03%, and for the current fiscal year, EXEL is expected to post earnings of $1.79 per share on revenue of $2.04 billion.
Shares of Exelixis, Inc. have gained 19.4% over the past month, and currently trade at a forward P/E of 15.05X and a P/CF of 34.97X.
The Medical - Biomedical and Genetics industry is in the top 29% of all the industries we have in our universe, so it looks like there are some nice tailwinds for ADMA and EXEL, even beyond their own solid fundamental situation.